Clinical trials: Postmenopausal Osteoporosis, open to volunteers
Osteoporosis, Postmenopausal, Osteoporotic Fractures
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporotic Fractures, Diphosphonates, Fracture Risk Assessment
- Trial name
- DASH-Osteo (NCT07120854)
- Testing
- Decision aid with decision analysis model, Decision aid alone, Usual Care
- Where
- Spain
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
- Trial name
- NCT07062978
- Testing
- QL1206, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteoporosis Risk, Osteoporosis, Postmenopausal
Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge
This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.
- Trial name
- NCT07034131
- Testing
- Osteo-Buddy, Usual Care
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- SingHealth Polyclinics
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteoporosis, Postmenopausal
Efficacy of OsteoBor in Postmenopausal Osteoporosis
This study aims to evaluate the impact of boron supplementation (OsteoBor) on bone health in postmenopausal women. The trial is a phase 2, randomised, double-blind, placebo-controlled study lasting one year
- Trial name
- NCT06809816
- Testing
- Sodium pentaborate pentahydrate
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tabriz University of Medical Sciences
Osteoporosis, Postmenopausal
Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis
The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with…
- Trial name
- NCT06655701
- Testing
- No intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Beylikduzu State Hospital
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Osteoporosis, Postmenopausal
Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.
- Trial name
- VASCO (NCT05228262)
- Testing
- Cohort follow-up
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand